Outlook Therapeutics (OTLK.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov14

Douglas Tsao Maintains Hold Rating on Outlook Therapeutics

23:41

Sep29

Outlook Therapeutics Completes Type A Meeting with FDA

13:37

Aug15

Outlook Therapeutics released FY2025 Q3 earnings on August 14 (EST), actual revenue USD 1.505 M (forecast USD 1.663 M), actual EPS USD -0.5499 (forecast USD -0.3525)

03:00

Outlook Therapeutics released FY2025 9 Months Earnings on August 14 EST, with actual revenue of USD 1.505 M and EPS of USD -1.3343

03:00

Jul1

Outlook Therapeutics Appoints Bob Jahr as CEO

12:06

Jun2

Outlook Therapeutics Launches First Bevacizumab Ophthalmic Formulation in Germany and the UK

11:44

Schedules & Filings

Schedules

Filings

Aug14

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 1.505 M, Net Income -20.15 M, EPS -0.5499

May15

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -46.36 M, EPS -1.5014

Feb14

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income 17.38 M, EPS 0.717

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change